title: Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
abstract: OBJECTIVE
  Currently adopted prognostic criteria for multiple myeloma (MM) still lack reliable predictive ability to select subsets of patients for different therapies, in particular for intensive treatment protocols. In this work we aimed to test the prognostic value of the MM Prognostic Index (MMPI), developed in 1996 by Grignani et al. from Pavia University as a clinical and investigational tool.
  
  
  METHODS
  Ninety-three MM patients were eligible for the study. All received initial induction therapy based on a standard 6-month melphalan + prednisone (M + P) protocol. Clinical and laboratory parameters, conventional staging and bone marrow infiltration percentage and cytopathology (BMIC) were assessed at diagnosis, while treatment response (TR) was evaluated using criteria after induction therapy. Cox's multivariate survival analysis was applied on prognostic data.
  
  
  RESULTS
  In our patients independent prognostic value was confirmed for British Medical Research Council staging, BMIC and TR, the three factors considered in MMPI. Risk classes obtained via MMPI identify patients with different outcomes; moreover, the index discriminates significantly among Stage II patients.
  
  
  CONCLUSIONS
  This new approach to MM prognosis is simple and reliable from the prognostic point of view; it refers not only to neoplastic mass, but also to intrinsic proliferative capacity of the malignant clone and to tumor-host interactions. We recommend its adoption in clinical practice and in the evaluation and design of therapeutic trials.
authors.affiliation: Divisione di Medicina Generale, Ospedale F. Del Ponte, Varese, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Bettini
authors.forename: M
authors.initials: M
authors.lastname: Tonolini
authors.forename: M
authors.initials: M
authors.lastname: Bernasconi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001536:Bence Jones Protein / Q000652:urine; D001853:Bone Marrow / Q000473:pathology; D002455:Cell Division; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015993:Life Tables; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D009367:Neoplasm Staging; D014411:Neoplastic Stem Cells / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D016016:Proportional Hazards Models; D012074:Remission Induction; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D001536:Bence Jones Protein; D008558:Melphalan; D011241:Prednisone